Five results showed a WT genotype for KRAS-tested mutations by cfDNA analysis, whereas tumor-tissue analysis showed a KRAS G13D mutation (n = 2), a KRAS G12D mutation (n = 2) or a KRAS G12V mutation (n = 1). This evidence concerns the gene KRAS and neoplasm.